Table 4 Adverse events with suspected relationship to everolimus
|
Everolimus 5 mg/day (n = 12) |
Everolimus 10 mg/day (n = 12) | |||||
|---|---|---|---|---|---|---|
| Adverse event, n (%) | All grades | Grade 3 | Grade 4 | All grades | Grade 3 | Grade 4 |
| Total | 12 (100) | 3 (25.0) | 0 | 12 (100) | 3 (25.0) | 0 |
| Hyperglycemia | 2 (16.7) | 0 | 0 | 5 (41.7) | 1 (8.3) | 0 |
| Fatigue | 2 (16.7) | 0 | 0 | 4 (33.3) | 1 (8.3) | 0 |
| Anemia | 1 (8.3) | 1 (8.3) | 0 | 3 (25.0) | 0 | 0 |
| Blood alkaline phosphatase increased | 1 (8.3) | 0 | 0 | 3 (25.0) | 1 (8.3) | 0 |
| Thrombocytopenia | 2 (16.7) | 1 (8.3) | 0 | 3 (25.0) | 0 | 0 |
| Hypokalemia | 3 (25.0) | 1 (8.3) | 0 | 2 (16.7) | 0 | 0 |
| Upper respiratory tract infection | 1 (8.3) | 1 (8.3) | 0 | 0 | 0 | |